EP1395276A4 - Struktur-modifizierte peptide und ihre verwendungen - Google Patents
Struktur-modifizierte peptide und ihre verwendungenInfo
- Publication number
- EP1395276A4 EP1395276A4 EP02731790A EP02731790A EP1395276A4 EP 1395276 A4 EP1395276 A4 EP 1395276A4 EP 02731790 A EP02731790 A EP 02731790A EP 02731790 A EP02731790 A EP 02731790A EP 1395276 A4 EP1395276 A4 EP 1395276A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modified peptides
- structurally modified
- structurally
- peptides
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29064601P | 2001-05-15 | 2001-05-15 | |
US290646P | 2001-05-15 | ||
PCT/US2002/015217 WO2002092120A1 (en) | 2001-05-15 | 2002-05-14 | Structurally modified peptides and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1395276A1 EP1395276A1 (de) | 2004-03-10 |
EP1395276A4 true EP1395276A4 (de) | 2004-12-29 |
Family
ID=23116948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02731790A Withdrawn EP1395276A4 (de) | 2001-05-15 | 2002-05-14 | Struktur-modifizierte peptide und ihre verwendungen |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1395276A4 (de) |
WO (1) | WO2002092120A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002951212A0 (en) * | 2002-09-04 | 2002-09-19 | Monash University | A method of modulating cellular activity and molecules for use therein |
WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033511A1 (en) * | 1997-02-05 | 1998-08-06 | Ludwig Institute For Cancer Research | Structurally modified peptides resistant to peptidase degradation |
WO2001070772A2 (fr) * | 2000-03-23 | 2001-09-27 | Pierre Fabre Medicament | Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
ES2318848T3 (es) * | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
US6218363B1 (en) * | 1996-08-28 | 2001-04-17 | Thomas Jefferson University | MHC peptides and methods of use |
-
2002
- 2002-05-14 WO PCT/US2002/015217 patent/WO2002092120A1/en not_active Application Discontinuation
- 2002-05-14 EP EP02731790A patent/EP1395276A4/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033511A1 (en) * | 1997-02-05 | 1998-08-06 | Ludwig Institute For Cancer Research | Structurally modified peptides resistant to peptidase degradation |
WO2001070772A2 (fr) * | 2000-03-23 | 2001-09-27 | Pierre Fabre Medicament | Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide |
Non-Patent Citations (9)
Title |
---|
AYYOUB MAHA ET AL: "Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: Application to the design of peptidase-resistant analogs", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 12, no. 9, 1998, pages 557 - 564, XP008037828, ISSN: 0951-4198 * |
BECK A ET AL: "Stability and CTL activity of N-terminal glutamic acid containing peptides.", THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY. JUN 2001, vol. 57, no. 6, June 2001 (2001-06-01), pages 528 - 538, XP002303302, ISSN: 1397-002X * |
BIANCO A ET AL: "N-Hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities.", JOURNAL OF PEPTIDE SCIENCE : AN OFFICIAL PUBLICATION OF THE EUROPEAN PEPTIDE SOCIETY. DEC 1998, vol. 4, no. 8, December 1998 (1998-12-01), pages 471 - 478, XP008037890, ISSN: 1075-2617 * |
BLANCHET J S ET AL: "A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 2001, vol. 167, no. 10, 15 November 2001 (2001-11-15), pages 5852 - 5861, XP002303301, ISSN: 0022-1767 * |
BRINCKERHOFF L H ET AL: "Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 29 OCT 1999, vol. 83, no. 3, 29 October 1999 (1999-10-29), pages 326 - 334, XP002303298, ISSN: 0020-7136 * |
GUICHARD G ET AL: "Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.", JOURNAL OF MEDICINAL CHEMISTRY. 5 OCT 2000, vol. 43, no. 20, 5 October 2000 (2000-10-05), pages 3803 - 3808, XP002303299, ISSN: 0022-2623 * |
QUESNEL A ET AL: "Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.", JOURNAL OF PEPTIDE SCIENCE : AN OFFICIAL PUBLICATION OF THE EUROPEAN PEPTIDE SOCIETY. MAR 2001, vol. 7, no. 3, March 2001 (2001-03-01), pages 157 - 165, XP008037820, ISSN: 1075-2617 * |
See also references of WO02092120A1 * |
VALMORI D ET AL: "ENHANCED GENERATION OF SPECIFIC TUMOR-REACTIVE CTL IN VITRO BY SELECTED MELAN-A/MART-1 IMMUNODOMINANT PEPTIDE ANALOGUES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 4, 1998, pages 1750 - 1758, XP000887160, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002092120A1 (en) | 2002-11-21 |
EP1395276A1 (de) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1463742A4 (de) | Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke | |
EP1390393A4 (de) | Pentapeptidverbindungen und deren verwendungen | |
IL160127A0 (en) | Tacis and br3 polypeptides and uses thereof | |
HUP0500989A2 (en) | Animicrobial polypeptides and their uses | |
EP1408978A4 (de) | Neue phenylamino-pyrimidine und ihre verwendungszwecke | |
PT1390516E (pt) | Novos vectores de expressão e uso dos mesmos | |
IL154553A0 (en) | Urocortin-iii and uses thereof | |
EP1414848A4 (de) | Replikin-peptide und ihre verwendungszwecke | |
EP1419175A4 (de) | Replikin-peptide und anwendungen | |
EP1462455A4 (de) | Neue peptide und deren medizinische verwendungen | |
IL131707A0 (en) | Acetylcholinesterase-derived peptides and uses thereof | |
GB0100196D0 (en) | Peptides | |
EP1408985A4 (de) | Neue pyridopyrimidone und ihre verwendungszwecke | |
HK1063486A1 (en) | Novel expression vectors and uses thereof | |
GB0026134D0 (en) | Peptides and their use | |
GB0109438D0 (en) | Peptides | |
EP1395276A4 (de) | Struktur-modifizierte peptide und ihre verwendungen | |
EP1367123A4 (de) | Neurotonin und dessen verwendung | |
SG10201403662QA (en) | Replikin peptides and uses thereof | |
GB0108752D0 (en) | Peptide epitopes and uses thereof | |
GB0102447D0 (en) | Protein variants and uses thereof | |
IL159495A0 (en) | Replikin peptides and uses thereof | |
IL158109A0 (en) | Replikin peptides and uses thereof | |
AUPR589701A0 (en) | Novel peptide and use thereof | |
IL149179A0 (en) | FcyRII-BINDING PEPTIDES AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 38/17 B Ipc: 7C 07K 14/47 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041116 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050203 |